Author Archives: Vanda Pinto

‘Robust’ Genetic Patient Data Open to Researchers via Fox DEN

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe are opening “robust” genetic data to researchers worldwide that could help in identifying markers of treatment response and disease progression, and ultimately may lead to better therapies for Parkinson’s disease. These new and de-identified (for privacy)…

Study Ties Swallowing Abilities to Disease Progression

Swallowing difficulties seem to be associated with progression of Parkinson’s disease, a study has found. Researchers found that high doses of levodopa can increase xerostomia — or dry mouth — and negatively affect the oral environment. Moreover, people with Parkinson’s seem to be unaware of their swallowing difficulties, which could lead to…

$10M Will Boost Research, Care, Education Programs

The Parkinson’s Foundation is investing an additional $10 million to support research, care, and education programs in order to improve the lives of people with Parkinson’s disease in the U.S. Part of the funding will go toward the PD GENEration: Mapping the Future of Parkinson’s Disease initiative,…

Valted Seq Acquires Rights to Develop Biomarker Assays

D&D Pharmatech’s new subsidiary, Valted Seq, announced it has acquired exclusive rights from Johns Hopkins University to develop multiple biomarker assays for the evaluation and management of neurodegenerative diseases, including Parkinson’s. “There are currently no clinically accepted biomarker assays available for Parkinson’s disease. An assay capable of…